This MedLibrary.org supplementary page on Sulpiride is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:
Related Sponsors
 |
|
|
Sulpiride
|
|
| Systematic (IUPAC) name | |
| 2-methoxy-N-((1-propylpyrrolidin-2-yl)methyl)- 5-sulfamoylbenzamide | |
| Identifiers | |
| CAS number | |
| ATC code | N05 N05 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C15H23N3O4S |
| Mol. mass | 341.427 g/mol |
| Pharmacokinetic data | |
| Bioavailability | 25–35% |
| Metabolism | ? |
| Half life | 7 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Sulpiride (sold as Meresa, Sulpirid Ratiopharm, Sulpirid Neuraxpharm, Bosnyl, Dogmatil, Eglonyl, Sulpiryd in Poland) is an anti-psychotic drug used mainly in the treatment of psychosis (e.g. schizophrenia) and depression. It is a substituted benzamide. Sulpiride is more commonly used in Europe and Japan. Levosulpiride is its purified levo isomer and is sold in India for similar purpose.So far it has not been approved in the US and Canada. The drug has strong chemical and clinical similarities to the novel anti-psychotic amisulpride.
Contents |
Pharmacology
Pharmacokinetics
Sulpiride is absorbed slowly from the GI-Tract. Its oral bioavailability is only 25 to 35% with marked interindividual differences. The peak plasma concentration is reached 4.5 hours after oral dosing. The usual half-life is 6 to 8 hours. Ninety-two percent is excreted unchanged in the urine. Sulpiride is usually given in 2 or 3 divided doses.
Pharmacodynamic properties
Sulpiride is a selective antagonist at postsynaptic D2-receptors. This action dominates in doses exceeding 600 mg daily. In doses of 600 to 1,600 mg sulpiride shows mild sedating and antipsychotic activity. Its antipsychotic potency compared to chlorpromazine is only 0.2 (1/5). In low doses (in particular 50 to 200 mg daily) its prominent feature is antagonism of presynaptic inhibitory dopamine receptors accounting for some antidepressant activity and a stimulating effect. Therefore, it is in these doses used as a second line antidepressant. Additionally, it alleviates vertigo.
Uses and dosage
- Productive psychosis: treatment with rather high doses—in excess of 600 mg daily.
- Long-term Treatment of negative (unproductive) psychosis: in moderate doses (approx. 600 mg daily)
- Treatment of depression and vertigo: in low to moderate doses (50 to 200 mg daily)
- Levosulpiride has been promoted as a gastrointestinal prokinetic agent
Contraindications and cautions
- Hypersensitivity to sulpiride
- Pre-existing breast cancer or other prolactin-dependent tumors
- Phaeochromocytoma
- Intoxication with other centrally active drugs
- Concomitant use of levodopa
- Caution : Pre-existing Parkinson's Disease
- Caution : Patients below 18 years of age (insufficient clinical data)
- Caution : Pre-existing severe heart disease/bradycardia, or hypokalemia (predisposing to long QT syndrome and severe arrhythmias)
- Caution : Patients with pre-existing epilepsy. Anticonvulsant therapy should be maintained.
Pregnancy and lactation
- Pregnancy: Animal studies did not reveal any embryo- or fetotoxic properties nor did limited human experience. Due to insufficient human data, pregnant women should be treated with Sulpiride only if strictly indicated. Additionally, the newborns of treated women should be monitored, because isolated cases of extrapyramidal side effects have been reported.
- Lactation: Sulpiride is found in the milk of lactating women. Since the consequences are unclear, women should not breastfeed during treatment.
Side effects
Sulpiride has fewer extrapyramidal side effects (dystonia, parkinsonism, tardive dyskinesia, and akathisia) than many of the older antipsychotic medications. Most of these do not seem to occur in a dose related manner. Other side effects occur infrequently (hypotension, rarely long-QT syndrome, dry mouth, sweating, nausea, activation or sedation, insomnia, allergic rash or pruritus). Isolated cases of the potentially life-threatening NMS (neuroleptic malignant syndrome) have been reported. Sulpiride should not be taken after 4 p.m. in order to avoid insomnia. The foremost problem with sulpiride is a strong stimulation of prolactin-secretion; whether this may contribute to the development of breast-cancer in women is currently not known.
- Levodopa : Sulpiride and levodopa have antagonistic effects.
- Alcohol : Sedation and hypotension may be potentiated.
- Antihypertensive agents : Hypotension may be potentiated (risk of postural collapse).
- Other central depressants : Increased sedation with negative impact on the capacity to drive or operate machinery.
Overdose
Sulpiride has a relatively low order of acute toxicity. Substantial amounts may cause severe but reversible dystonic crises with torticollis, protrusion of the tongue, and/or trismus. In some cases all the classical symptoms typical of severe Parkinson's Disease may be noted; in others, over-sedation/coma may occur. The treatment is largely symptomatic. Some or all extrapyramidal reactions may respond to the application of anticholinergic drugs such as Biperiden or Benztropine. All patients should be closely monitored for signs of long-QT syndrome and severe arrhythmias.
GHB receptor
The benzamide neuroleptics (including amisulpride and sulpiride) have been shown to activate the endogenous gamma-hydroxybutyrate receptor in vivo at theraputic concentrations.[1] Sulpiride was found in one study in rats to upregulate GHB receptors.[2]
GHB has neuroleptic properties and it is believed binding to this receptor may contribute to the effects of these neuroleptics.
References
- ^ Displacement of [3H] gamma-hydroxybutyrate binding...[Eur J Pharmacol. 1994] - PubMed Result
- ^ Ratomponirina C, Gobaille S, Hodé Y, Kemmel V, Maitre M (April 1998). "Sulpiride, but not haloperidol, up-regulates gamma-hydroxybutyrate receptors in vivo and in cultured cells". Eur. J. Pharmacol. 346 (2-3): 331–7. PMID 9652377.
- British National Formulary, 2005
|
|||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||
Wikipedia content modification information:
- This page was last modified on 17 September 2008, at 20:45.
Wikipedia Authorship and Review
Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.
Wikipedia Usage Guidelines
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Sulpiride".
The URL for this specific entry is:
All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.